The estimated Net Worth of Peter C. Brandt is at least $55.2 Thousand dollars as of 16 August 2022. Peter Brandt owns over 105,263 units of In8 Bio stock worth over $55,216 and over the last 14 years Peter sold INAB stock worth over $0.
Sign up
Peter Brandt INAB stock SEC Form 4 insiders trading
Peter has made over 3 trades of the In8 Bio stock since 2011, according to the Form 4 filled with the SEC. Most recently Peter bought 105,263 units of INAB stock worth $200,000 on 16 August 2022.
The largest trade Peter's ever made was buying 125,000 units of In8 Bio stock on 8 September 2011 worth over $146,250. On average, Peter trades about 14,181 units every 222 days since 2010. As of 16 August 2022 Peter still owns at least 182,473 units of In8 Bio stock.
You can see the complete history of Peter Brandt stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
What's Peter Brandt's mailing address?
Peter's mailing address filed with the SEC is C/O IN8BIO, INC., 350 5TH AVE. SUITE 5330, NEW YORK, NY, 10118.
Insiders trading at In8 Bio
Over the last 3 years, insiders at In8 Bio have traded over $0 worth of In8 Bio stock and bought 5,038,673 units worth $10,468,296 . The most active insiders traders include Aaron G.L.Bios Equity Partn..., Leslie W.Bios Fund Ii Nt, L..., and Emily Transcend Partners Op.... On average, In8 Bio executives and independent directors trade stock every 32 days with the average trade being worth of $63,860. The most recent stock trade was executed by Jeremy R. Graff on 13 September 2023, trading 2,500 units of INAB stock currently worth $2,375.
What does In8 Bio do?
IN8bio, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of gamma-delta T cell therapies for the treatment of cancers. The company develops INB-200, a genetically modified autologous gamma-delta T cell product candidate that is in Phase I clinical trial for the treatment of solid tumors; and INB-100, an allogeneic product candidate, which is in Phase I clinical trial to treat patients with acute leukemia undergoing hematopoietic stem cell transplantation. It also develops INB-400 and INB-300 that is in preclinical Phase for treatment of various solid tumor cancers. The company was formerly known as Incysus Therapeutics, Inc. and changed its name to IN8bio, Inc. in August 2020. IN8bio, Inc. was incorporated in 2016 and is headquartered in New York, New York.
What does In8 Bio's logo look like?
Complete history of Peter Brandt stock trades at In8 Bio
In8 Bio executives and stock owners
In8 Bio executives and other stock owners filed with the SEC include:
-
William Ho,
Co-Founder, Pres, CEO & Director -
Dr. Lawrence S. Lamb Ph.D.,
Exec. VP, Co-Founder & Chief Scientific Officer -
Dr. Trishna Goswami M.D.,
Chief Medical Officer -
Charles Butler,
VP of Investor Relations & Communications -
Dr. Kate Rochlin Ph.D.,
Chief Operating Officer -
Patrick McCall CPA,
Chief Financial Officer -
Emily Fairbairn,
-
Travis Whitfill,
-
Jeremy R. Graff,
-
Luba Greenwood,
-
Alan S. Roemer,
-
Corinne Epperly,
-
Lawrence Lamb,
EVP and CSO -
Leslie W.Bios Equity Partne...,
-
Aaron G.L.Bios Fund Ii, Lpb...,
-
Peter C. Brandt,
-
William Tai Wei Ho,
PRESIDENT AND CEO -
Aaron G.L.Bios Fund Iii, Lp...,
-
Emily Transcend Partners Op...,
-
Leslie W.Bios Fund Ii Nt, L...,
-
Leslie W.Cavu Management, L...,
-
Aaron G.L.Bios Capital Mana...,
-
Leslie W.Bios Fund Ii Nt, L...,
-
Aaron G.L.Bios Equity Partn...,
-
Aaron G.L.Bios Fund Ii Nt, ...,
-
Leslie W.Bios Equity Partne...,
-
Kate Rochlin,
Chief Operating Officer -
Patrick Mc Call,
CHIEF FINANCIAL OFFICER -
Trishna Goswami,
Chief Medical Officer